GleamWall
中文EN

TRAX First Tracks Biotherapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2091349 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets11.4%
Debt / equity0.00x
Current ratio9.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$23.85M$25.64M$33.95M$33.32M$39.27M$41.47M
SG&A expense$9.00M$9.29M$18.86M$11.73M$6.63M$9.81M
Operating income-$32.84M-$34.94M-$52.81M-$45.06M-$45.90M-$51.28M
Net income-$31.36M-$33.37M-$50.48M-$41.86M-$42.45M-$47.20M
EBITDA-$32.75M-$34.83M-$52.69M-$44.92M-$45.76M-$51.13M
EPS (basic)-0.88-0.95—-1.50-1.47—
EPS (diluted)-0.88-0.95—-1.50-1.47—
Weighted avg. shares (diluted)35.75M35.00M—27.83M28.81M—
Balance sheet
Cash & equivalents$155.63M$168.02M$248.47M$109.83M$44.30M$98.64M
Short-term investments$0$0$37.99M———
Current assets$165.72M$177.75M$289.40M———
PP&E, net$979,000$1.07M$1.17M———
Total assets$170.46M$183.14M$290.58M———
Current liabilities$18.09M$12.45M$33.11M———
Total liabilities$19.45M$14.34M$33.11M———
Shareholders' equity$151.01M$168.80M$257.46M$231.64M$270.66M$357.72M
Shares outstanding35.90M35.39M————
Cash flow statement
Operating cash flow-$17.05M-$31.92M-$32.56M-$30.69M-$38.64M-$45.01M
Capital expenditure$0$25,000$17,000$12,000$39,000$35,000
Free cash flow-$17.05M-$31.94M-$32.58M-$30.70M-$38.68M-$45.04M
Investing cash flow$0-$25,000$34.98M$103.28M$36.40M$14.85M
Financing cash flow$4.66M-$48.51M$7.85M-$7.06M-$52.10M$5.72M
Depreciation & amortization$92,000$105,000$125,000$140,000$142,000$146,000
Stock-based compensation$8.90M$8.32M$11.50M$9.85M$7.66M$7.75M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.